Why BioLineRx Ltd. (BLRX) Surged Last Week

We recently published a list of Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week. In this article, we are going to take a look at where BioLineRx Ltd. (NASDAQ:BLRX) stands against other firms that led last week’s charge.

BioLineRx surged by 43.44 percent week-on-week as investors cheered the positive results from the single-arm pilot phase of the CheMo4METPANC Phase 2 combination clinical trial, which it was set to present at an ongoing oncology annual meeting.

In a statement, BioLineRx Ltd. (NASDAQ:BLRX) said that the CheMo4METPANC trial is evaluating its CXCR4 inhibitor motixafortide for the potential treatment of pancreatic cancer.

A pharmacist preparing a dose of an immuno-oncology agent for research use.

Updated results from the trial showed that four of 11 patients remained progression-free after more than a year, while two underwent definitive treatment for mPDAC, a highly aggressive, lethal form of pancreatic cancer. Another patient had complete resolution of all radiologically detected liver lesions, and one had a sustained partial response.

“The data that continue to emerge from the pilot phase of the CheMo4METPANC Phase 2 study are extremely encouraging,” said BioLineRx Ltd. (NASDAQ:BLRX) CEO Philip Serlin, saying that he was looking forward to the results of the ongoing randomized portion of the study.

Overall, BLRX ranks 10th on our list of firms that led last week’s charge. While we acknowledge the potential of BLRX, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BLRX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.